Johnson & Johnson Reports Q1 2026 Earnings, Beats Estimates but Faces Patent Expiry Concerns
Johnson & Johnson exceeded earnings estimates in Q1 2026, but its stock price fell slightly after the report. The company reported strong sales for drugs like Darzalex and Tremfya, but concerns over the patent expiry of Stelara, which led to a significant drop in sales, dampened investor sentiment.
Tickers: $JNJ
Topics: Drug Sales Earnings Patent Expiry Stock Price Movement